BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28869453)

  • 1. Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3.
    Lin L; Chen D; Xiang ZF; Pei RZ; Zhang PS; Liu XH; Du XH; Lu Y
    Cancer Biomark; 2017 Aug; 20(2):217-224. PubMed ID: 28869453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
    Ma Y; Liu W; Zhang L; Jia G
    Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells.
    Cao Y; Qiu GQ; Wu HQ; Wang ZL; Lin Y; Wu W; Xie XB; Gu WY
    Mol Med Rep; 2016 Oct; 14(4):3469-75. PubMed ID: 27571872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L; Ma YP; Jia G
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
    Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
    Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW
    Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of the effects
    Tian Y; Li LH; Yang GZ; Chen WM
    Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):976-981. PubMed ID: 27995884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Apoptotic Effects of Bortezomib and Methylstat on Multiple Myeloma Cells.
    Kacı FN; Kiraz Y; Çekdemir D; Baran Y
    Arch Med Res; 2020 Apr; 51(3):187-193. PubMed ID: 32111493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
    Zhang HR; Chen JM; Zeng ZY; Que WZ
    J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
    Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
    Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
    Zhao Y; Zhang K; Li G; Zhang X; Shi D
    PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of cinobufagin on apoptosis in U-2OS osteosarcomas cells].
    Cao F; Kang X; Wang L
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2014 Mar; 28(3):349-53. PubMed ID: 24844018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAY-11-7082 induces apoptosis of multiple myeloma U266 cells through inhibiting NF-κB pathway.
    Wang Y; Zhang XL; Sun CM
    Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2564-2571. PubMed ID: 29771406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
    Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
    J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
    Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
    Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of PCI-32765 and bortezomib on proliferation and apoptosis of B-cell tumor cell lines and its mechanisms].
    Deng Y; Tao SD; Zhang X; He ZM; Chen Y; Deng ZK; Li YY; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1178-82. PubMed ID: 24156429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of sorafenib on proliferation and apoptosis of human multiple myeloma cell RPMI 8226].
    Zhou NC; Liu BL; Qi MY; Xu B; Liu X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1331-5. PubMed ID: 25338583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in protein profiles of multiple myeloma cells in response to bortezomib.
    Turan T; Sanlı-Mohamed G; Baran Y
    Leuk Lymphoma; 2013 May; 54(5):1061-8. PubMed ID: 23025401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.